Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of July 22, 2024
- Author
- Healio
- Published
- Thu 25 Jul 2024
- Episode Link
- http://sites.libsyn.com/408806/rheumatology-edition-top-headlines-for-week-of-july-22-2024
In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Read the full coverage here:
Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years
Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription
FDA approves biosimilar Pyzchiva for all approved Stelara indications
Tofacitinib effective for juvenile idiopathic arthritis through 4 years
Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes
References:
Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094.
Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277.
Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378.
Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.
